title: The inhibitory effect of anti-adhesion molecule antibodies on eosinophil infiltration in cutaneous late phase response in Balb/c mice sensitized with ovalbumin (OVA).
abstract: In this study, we investigated the involvement of the adhesion molecules intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), very late activation antigen-4 (VLA-4), lymphocyte function-associated antigen 1 (LFA-1) and macrophage antigen-1 (Mac-1) on eosinophil infiltration in the cutaneous late phase response (LPR) in OVA-sensitized Balb/c mice by two approaches, immunostaining and inhibition assays with each monoclonal antibody. The eosinophil infiltration into the skin reached a peak at 12 hr after an intradermal challenge with OVA. Infiltrated eosinophils and mononuclear cells in the skin expressed Mac-1 (eosinophils: 38.9 +/- 1.55%, mononuclear cells: 51.2 +/- 2.15%), LFA-1 (eosinophils: 33.3 +/- 0.95%, mononuclear cells: 23.1 +/- 1.07%) and VLA-4 (eosinophils: 14.3 +/- 1.6%, mononuclear cells: 17.2 +/- 1.38%) at 12 h. Intraperitoneal administration of anti-mouse ICAM-1, VCAM-1, and VLA-4 monoclonal antibodies (mAb) before the challenge decreased the eosinophil infiltration by 66.2%, 61.0%, and 54.0%, respectively. On the other hand, pretreatment with anti-mouse LFA-1 mAb or Mac-1 mAb did not significantly decrease the infiltration. These results suggest that VCAM-1/VLA-4 interaction and ICAM-1 play important roles in eosinophil infiltration in cutaneous LPR.
authors.affiliation: Department of Dermatology, Nagasaki University School of Medicine, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Hakugawa
authors.forename: S J
authors.initials: SJ
authors.lastname: Bae
authors.forename: Y
authors.initials: Y
authors.lastname: Tanaka
authors.forename: I
authors.initials: I
authors.lastname: Katayama
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules / Q000276:immunology*; D004396:Coloring Agents; D003872:Dermatitis / Q000276:immunology* / Q000473:pathology; D004804:Eosinophils / Q000276:immunology* / Q000473:pathology; D005260:Female; D007114:Immunization; D007150:Immunohistochemistry; D007271:Injections, Intradermal; D039041:Integrin alpha4beta1; D016023:Integrins / Q000276:immunology; D018799:Intercellular Adhesion Molecule-1 / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000473:pathology; D016169:Lymphocyte Function-Associated Antigen-1 / Q000276:immunology; D016177:Macrophage-1 Antigen / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000009:adverse effects / Q000276:immunology*; D016201:Receptors, Lymphocyte Homing / Q000276:immunology; D016029:Receptors, Very Late Antigen / Q000276:immunology; D015842:Serine Proteinase Inhibitors / Q000009:adverse effects / Q000276:immunology*; D012867:Skin / Q000276:immunology* / Q000473:pathology; D019010:Vascular Cell Adhesion Molecule-1 / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D004396:Coloring Agents; D039041:Integrin alpha4beta1; D016023:Integrins; D016169:Lymphocyte Function-Associated Antigen-1; D016177:Macrophage-1 Antigen; D016201:Receptors, Lymphocyte Homing; D016029:Receptors, Very Late Antigen; D015842:Serine Proteinase Inhibitors; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D010047:Ovalbumin